Clinical Trials Sector Scorecard, Q2 2022 Update – Thematic Research

Pages: 16 Published: June 30, 2022 Report Code: GDHCHT336

In Q2 2022, there was increased activity in the virtual care space. Compared to Q1 2022, Novo Nordisk initiated more trials with virtual components and posted more jobs related to virtual care. Daiichi Sankyo and Takeda are planning a study in Japan that will look at the feasibility of using a wearable device to track lifestyle habits. Sanofi announced several social initiatives, including the successful pricing of its first bond linked to improving access to essential medicine, the launch of its Diversity, Equity & Inclusion (DE&I) board, and the launch of Foundation S – The Sanofi Collective, its philanthropic endowment fund.

The clinical trials sector scorecard report offers in-depth research into a specific theme (such as AI or cybersecurity). The report identifies winners and losers based on technology leadership, market position, and other factors. It also covers all themes within a sector, giving readers a strong sense of how everything fits together and how conflicting themes might interact with one another. Moreover, each sector scorecard identifies the companies that are most likely to succeed in a world filled with disruptive threats.

What are the key events that have impacted the clinical trials thematic scorecard in Q2 2022?

Some of the key events that have impacted the clinical trials thematic scorecard in Q2 2022 are as follows:


In May 2022, Merck KGaA announced that over the next five years, it was going to invest at sites in Germany, China, France, Switzerland, Ireland, and the US that will focus on targets for water consumption, waste management, and energy efficiency, to support meeting its goal to be climate-neutral by 2040.

Virtual care

 There were several interesting deals in the virtual care and digital health space in Q2 2022. Boehringer Ingelheim was sponsoring the UK’s first digital health training program for all NHS frontline staff. In May, Pfizer acquired ResApp Health, a digital health company developing smartphone apps for the diagnosis and management of the respiratory disease. Additionally, Roche partnered with Kaiku Health in May 2022 to offer cancer symptom management and support to clinics and patients via a digital platform.


In Q2 2022, many strategic partnerships in AI were forged, but which had no overall impact on company scores. GSK and PathAI partnered in April this year to accelerate R&D programs in oncology and non-alcoholic steatohepatitis (NASH) by leveraging PathAI’s digital pathology technologies including its AIM-NASH tool. Standigm enter into an agreement with Merck Korea in May 2022 to accelerate its drug discovery research by adopting Merck’s AI software SYNTHIA. In June 2022, Owkin announced that it will use AI to design clinical trials for BMS, with an initial focus on cardiovascular disease.

For more insights on the key events impacting the clinical trial thematic scorecard, download a free report sample

Market Report Overview

Key events ESG, Virtual Care, and AI


  • GlobalData’s Clinical Trials Thematic Scorecard report provides a top-down, comprehensive outlook for key players in the clinical trial sector over the next two to four years.
  • These themes are Virtual Care, Rare Disease, Orphan Designated Drugs, Strategic Alliances, Real-world Evidence, AI, ESG, Cybersecurity, Cloud Computing, and Blockchain.
  • The scorecard includes 53 companies from across the industry, including biopharmaceutical companies, biosimilar, and generic manufacturers, contract development and manufacturing organizations (CDMOs), and contract research organizations (CROs).
  • It is important to note that this scorecard is not an assessment of the current performance of a company in a theme, but a view of future performance based on current levels of activity and investment.
  • The methodology section contains information on what data sources were used to generate the thematic scores for each company.
  • The scorecard is live on the PIC and will be updated quarterly.

Reasons to Buy

  • Identify the key clinical trial themes for the next 2-4 years and learn how they will impact the market.
  • Understand which key themes should be addressed to drive the share price.
  • Understand which companies are best positioned for success within critical themes and why.
  • Learn which companies have underinvested in key themes and are most vulnerable to disruption.
  • Help companies adapt their strategy to anticipate and benefit from these themes as they play out.
  • Help identify future winners and losers in drug development to inform partnership strategies.

Table of Contents

Executive Summary


• Pharma Theme Map

Clinical Trials Scorecard: Key Q2 2022 Updates

• Company Screen

• Thematic Screen

• Valuation Screen

Our Thematic Research Methodology

• How Our Pharma Scores Are Generated

Related Reports

About the Authors

About GlobalData

Frequently Asked Questions

The key events that have impacted the clinical trials thematic scorecard in Q2 2022 are ESG, virtual care, and AI.

Some of the key themes associated with the clinical trial market are empowered patient, geopolitics, cell and gene therapy, demographic changes, strategic alliances, big data, wearable tech, drug pricing and reimbursement, outsourcing, and cybersecurity.

Some of the key companies associated with the clinical trial market are Merck KGaA, Sanofi, Novo Nordisk, Daiichi Sankyo, Pfizer, Roche, Boehringer Ingelheim, GSK, and Bristol Myers Squib.

The key types of screens available in the clinical trial theme sector scorecard are thematic screen, valuation screen, and risk screen.


Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

Still undecided about purchasing this report?

Enquire Before Buying

Request a Free Sample


“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods